Health Canada
Symbol of the Government of Canada

Common menu bar links

About Health Canada

Access to Information Requests Completed - August 2014

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the Month of August 2014
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2010-00371 Documents related to the Natural Health Products (Unprocessed Product Licence Applications) Regulations. (Dec 1, 2009 to Jun 15, 2010). Disclosed in part 3,007
A-2011-01632 Information regarding the following:
  • Liver, Natural Product Number (NPN) 80022753by New Roots Herbal Inc.
  • Milk Thistle Plus, NPN 80005817 by Flora Manufacturing & Distributing Ltd
  • Milk Thistle, NPN 80000018 by Jamieson Laboratories Ltd
Disclosed in part 486
A-2012-01210 Adverse Reaction Report (AER) for Aspirin. Report numbers: 000428019, 000428111, 000428129, 000436994, 000437605, 000442133. Disclosed in part 26
A-2012-01624 Adverse Reaction Report (AER) for Cymbalta. Report numbers: 000418081, 000418533, 000419804, 000420855, 000422299, 000423172, 000423686, 000425090, 000425640, 000425875. Disclosed in part 35
A-2012-01632 Adverse Reaction Report (AER) for Zyprexa. Report numbers: 000424857, 000425700, 000426056, 000427165, 000436065, 000436225, 000438184, 000441342, 000442005, 000426115. Disclosed in part 26
A-2013-01040 All correspondence and briefing notes in regards to the department inadvertently mailing out form letters to individuals enrolled in the Marihuana Medical Access Program through regular mail instead of the usual registered mail. (Nov 21, 2013 to Nov 26, 2013). Disclosed in part 249
A-2013-01197 Documents regarding the Marihuana Medical Access Program referring to the confidentiality or privacy of information provided by participants, or personal information of participants. (Jan 1, 2009 to Jan 13, 2014). Disclosed in part 341
A-2013-01199 Documents relating to how it came to be that the phrase Marihuana Medical Access Program (or similar French phrase) was visible on the front of the envelopes containing the letter from Health Canada sent in November 2013. And any communications with Canada Post regarding the distribution of the letter. (Jan 1, 2013 to Jan 13, 2014). Disclosed in part 432
A-2013-01276 Documents pertaining to the communications plan for the leak of the document Health Canada Library Services: Analysis and Recommendations in 2014. Disclosed in part 466
A-2013-01385 Minutes from the 2010-2012 Health Canada Branch Executive Committee meetings when the Pathway for Licensing Natural Health Products Making Modern Health Claims was discussed, especially the Annex II: Combination Ingredients (also known as the sub-therapeutic ingredients policy). All disclosed 2
A-2013-01407 Documents received from the company Les Équipements de Piscine Carvin Inc., in connection with the submission of their registration applications for their salt chlorine generators, models CGS60 and CGS120. (Registration numbers: 30794 and 30942). All disclosed 334
A-2013-01429 Document regarding the names of the third parties and contractors that reviewed the New Drug Submission (Control #162924) for Ferriprox. (Jan 1, 2014 to Mar 7, 2014). No records exist 0
A-2013-01559 Marihuana for Medical Purposes Regulations license applications: copy of Municipal Notifications before submitting an application for a new or amended licence to produce. Disclosed in part 15
A-2014-00004 Most recent data regarding Medical Device Establishment Licenses (MDEL): Number of Licenses currently issued, type of activity of the MDEL holders, the amount of User Fees collected, average time it takes for a new MDEL application to be reviewed. All disclosed 4
A-2014-00021 Information regarding PATHOCEPT, Drug Identification Number (DIN) 02338688. Disclosed in part 42
A-2014-00054 Letter dated May 25, 2012 regarding the 2002 edition of Purdue Pharma's book entitled Managing Pain. Disclosed in part 2
A-2014-00123 Marihuana for Medical Purposes Regulations documents for applications, security and quality assurance regarding the license producers Tweed Inc. and Whistler Medical Marijuana Co. Disclosed in part 243
A-2014-00128 Information regarding Experdry Forte Solution, Natural Product Number (NPN) 80018918 by Seaford Pharmaceuticals Inc. Disclosed in part 3
A-2014-00137 Adverse Reaction Report (AER) for ALVESCO. Report numbers: 000488868, 000544254. Disclosed in part 9
A-2014-00157 Application forms and authorization letter from Tweed Marijuana Inc and Metrum Ltd requesting to purchase starting materials from personal production growers in British Columbia. Disclosed in part 40
A-2014-00203 Documents regarding Health Canada providing support to other jurisdictions in relation to the Wind Turbine Noise and Health Study. Disclosed in part 40
A-2014-00258 Emails regarding a moratorium on neonicotinoids. (Jun 1, 2013 to Oct 31, 2013). Disclosed in part 57
A-2014-00261 Documents pertaining to the Privacy Impact Assessments on the International Health Regulations. (Apr 1, 2013 to May 23, 2014). Disclosed in part 19
A-2014-00275 List of all Marihuana Producers who have applied under the Marihuana for Medical Purposes Regulations (MMPR) for approval of a license but have not yet been approved or have been refused. (Jun 1, 2013 to May 27, 2014). Disclosed in part 18
A-2014-00276 Adverse Reaction Report (AER) for Perindopril. Report numbers: 000411616, 000416053, 000469068, 000519184, 000524317, 000470971. Disclosed in part 10
A-2014-00285 Adverse Reaction Report (AER) for Isentress. Report numbers: 000504641, 000495311, 000480812, 000479928, 000469288, 000467521, 000450246, 000439853. Disclosed in part 31
A-2014-00323 Adverse Reaction Report (AER) for Integrilin. Report numbers: 000503502, 000471655. Disclosed in part 6
A-2014-00333 Notice of Compliance with conditions (NOC/c) for Ziagen. (NOC/c June 4, 1999). Disclosed in part 2
A-2014-00335 Notice of Compliance with conditions (NOC/c) for Rilutek. (NOC/c August 30, 2000). Disclosed in part 1
A-2014-00337 Notice of Compliance with conditions (NOC/c) for Viread. (NOC/c March 18, 2001). Disclosed in part 5
A-2014-00340 Adverse Reaction Report (AER) for Perindopril. Report numbers: 000529826, 000526162, 000551914, 000555858, 000508006, 000551700, 000556675. Disclosed in part 18
A-2014-00361 Adverse Reaction Report (AER) for Perindopril. Report numbers: 000568964, 000560623, 000565440, 000568227, 000572327, 000576602. Disclosed in part 11
A-2014-00366 Adverse Reaction Report (AER). Report numbers: E2B_00011365, 000525216. Disclosed in part 18
A-2014-00377 The list of briefing notes that were prepared or forwarded to the Minister of Health Canada. (May 20, 2014 to Jun 17, 2014). Disclosed in part 14
A-2014-00379 All briefing notes and research material regarding post-market surveillance before the Standing Senate Committee on Social Affairs, Science and Technology on October 3, 2012. All disclosed 88
A-2014-00380 All briefing notes and research material regarding of-label use before the Standing Senate Committee on Social Affairs, Science and Technology on April 17, 2013. All disclosed 56
A-2014-00417 Job description of any employee involved with compliance of producers and dispensaries under Marihuana Medical Access Regulations and Marihuana for Medical Purposes Regulations. (Apr 1, 2014 to Jul 3, 2014). Disclosed in part 53
A-2014-00418 All briefing notes related to the role of marihuana dispensaries under the new regulatory regime. (Aug. 1, 2013 to Jul 1, 2014). No records exist 0
A-2014-00431 Adverse Reaction Report. Report number: E2B_00031100. Disclosed in part 16
A-2014-00432 Adverse Reaction Report (AER). Report number: E2B_00030850. All disclosed 18
A-2014-00445 Adverse Reaction Report (AER) for Pradaxa. Report number: 000573815. Disclosed in part 1
A-2014-00446 5th International Wind Turbine Noise Conference held on August 27-30 2013: List of the subject matter experts and supporting references relied upon by Health Canada regarding the statement “Despite community concerns regarding potential infrasound impacts (<16Hz) the subject matter experts seem to agree that this is a non-issue and that more attention should be directed towards low frequency noise (16-60Hz), tones and amplitude modulation and how to better model these impacts, including how these change across the seasons”. No records exist 0
A-2014-00447 5th International Wind Turbine Noise Conference held on August 27-30 2013: Details of the strengths and limitations of the study during question periods and informal discussions. No records exist 0
A-2014-00448 Documents relied upon to support the statement that the Wind Turbine Noise Health Study will not be definitive. No records exist 0
A-2014-00450,
A-2014-00451
and
A-2014-00452
5th International Wind Turbine Noise Conference on August 27-30 2013: Inaccurate and misleading statements. No records exist 0
A-2014-00453 Ministerial Executive Correspondence System #13-005499-963: Statement made in relation to payments for blood and plasma donations. No records exist 0
A-2014-00460 Adverse Reaction Report (AER) for Perindopril/Indapamide. Report numbers: 000426221, 000559858. Disclosed in part 10
A-2014-00462 Information regarding MIRAPEX ER, Drug Identification Numbers (DIN) 02354047, 02354055, 02354063, 02354071, 02354098. All exempted 0
A-2014-00467 Memo (dated June 8, 1998) from the Occupational Health and Safety Agency sent to Canada Revenue Agency. No records exist 0
A-2014-00469 Documents regarding at statement made during the Denver Noise Conferences 2013 that the World Health Organisation (WHO) has stated in writing, that the WHO 2009 night noise guidelines can be applied to industrial wind turbines. No records exist 0
A-2014-00485 Adverse Reaction Report. Report number: 000459440. Disclosed in part 3
A-2014-00494 Documents regarding the competitive process for the EX-3 Director General of the National Microbiology Laboratory. (Jan 1, 2014 to Jun 30, 2014). All disclosed 1
A-2014-00495 A listing of the Access to Information requests submitted to Health Canada. (Jun 1, 2014 to Jun 30, 2014). Disclosed in part 8
A-2014-00502 Adverse Reaction Report (AER) for MICARDIS PLUS. Report number: 000414287. Disclosed in part 3
A-2014-00507 Adverse Reaction Report (AER). Report number: 000581538. Disclosed in part 3
A-2014-00514 Documents regarding the amount paid to Express Scripts Canada in bonuses, rewards, or earnings or any other form of remuneration or benefit for prescription audit recoveries under the Non Insured Health Benefits program and how much money has been reclaimed from pharmacies and medical supply companies. (Jan 1, 2010 to Jul 21, 2014). All disclosed 2
A-2014-00518 Adverse Reaction Report (AER) for Menactra & Typhim VI. Report number: 000584031. Disclosed in part 2
A-2014-00519 Adverse Reaction Report (AER) for Vaxigrip. Report number: 000594949. Disclosed in part 4
A-2014-00520 Adverse Reaction Report (AER) for Adacel. Report number: 000596104. Disclosed in part 1
A-2014-00521 Adverse Reaction Report (AER) for Adacel-Polio. Report number: 000597854. Disclosed in part 1
A-2014-00526 List of all First Nations and Inuit Health Branch Nursing Stations in Canada identifying those in which Federal funding has been transferred. All disclosed 51
A-2014-00530 Adverse Reaction Report (AER) for Epival. Report number: 000585936. Disclosed in part 1
A-2014-00532 Adverse Reaction Report (AER) for Biaxin. Report numbers: 000587692, 000590604, 000592063, 000592215, 000598972. Disclosed in part 11
A-2014-00533 Adverse Reaction Report (AER) for Androgel. Report numbers: 000581011, 000592119. Disclosed in part 3
A-2014-00534 Adverse Reaction Report (AER) for Rythmol. Report numbers: 000588444, 000599505. Disclosed in part 3
A-2014-00536 Adverse Reaction Report (AER) for Lipidil. Report numbers: 000584800, 000584801, 000584802, 000584803, 000584804. Disclosed in part 5
A-2014-00554 Reports on the Centers for Disease Control and Prevention lab inspection conducted and led by the Public Health Agency of Canada, and documents showing who paid for the inspection and whether there was any memorandum or agreement with the Canadian government with regard to this inspection. No records exist 0
A-2014-00558 Adverse Reaction Report (AER). Report numbers: 000568949, 000577728, 000567852. Disclosed in part 8
A-2014-00559 Policy decisions made regarding the impact of the medical marihuana injunction motion and/or the court's ruling in Allard v. Canada (decision released March 21, 2014) on the processing of applications to become licensed producers under the Marihuana for Medical Purposes Regulations. (Jan 31, 2014 to Jul 7, 2014). No records exist 0
A-2014-00577 Adverse Reaction Report (AER) for Plaquenil. Report number: 000152319. Disclosed in part 2
A-2014-00601 Adverse Reaction Report (AER) for PRADAXA. Report number: 000589441. Disclosed in part 2
A-2014-00609 List of the members of the Health Canada committee for the James Bay region located in Timmins that consent or deny requests for mental health support. No records exist 0
A-2014-00622 Blank patient informed consent documents submitted as part of any approval process for any clinical trials of the drug HUMIRA (ADALIMUMAB) conducted and identify the trial with respect to each such form provided. (Jan 1, 1997 to Dec 31, 2001). No records exist 0